A PHASE 2B, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED, 3-ARM STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF SHP607 IN PREVENTING CHRONIC LUNG DISEASE THROUGH 12 MONTHS CORRECTED AGE COMPARED TO STANDARD NEONATAL CARE IN EXTREMELY PREMATURE INFANTS.

Registry ID

OHB-607-202 (SHP607-202)

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

OHB NEONATOLOGY LTD

Start date

2019-09-18

Last update

2019-07-31

Conditions

• LUNG DISEASE

Related clinical trials

• AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH FIBROTIC LUNG DISEASE
• REDUCING RESPIRATORY SYMPTOMS OF PULMONARY IRRADIATION IN INTERSTITIAL LUNG DISEASE (RESPIRE-ILD): A 2X2 FACTORIAL RANDOMIZED PHASE II TRIAL TESTING N-ACETYL CYSTEINE AND DEXAMETHASONE
• PIONEERING PRE- AND POST-OPERATIVE INTEGRATIVE CARE TO IMPROVE THORACIC CANCER QUALITY OF CARE: THE THORACIC PERI-OPERATIVE INTEGRATIVE SURGICAL CARE EVALUATION (POISE) TRIAL - STAGE III
• PULMONARY IMAGING REGISTRY (PIMREGISTRY) FOR INNOVATION IN RESPIRATORY MEDICINE
• IMAGING MEASURES OF RESPIRATORY HEALTH REGISTRY (IMRH)
• SINGLE-CENTRE STUDY EXPLORING THE UTILITY OF HYPERPOLARIZED 129XE MAGNETIC RESONANCE IMAGING IN HEALTHY VOLUNTEERS AND PATIENTS WITH LUNG DISEASE

View on source registry